Company
CYTOSOLIX
Cancer has a universal weakness. We enable every drug to exploit it.
Also known as CYTOSOLIX, INC.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- CYTOSOLIX, INC.
Claim, correct or request removal
Record updated 28 September 2026
About
Cytosolix redesigns small molecule drugs to target them to tumors – widening therapeutic windows by exploiting a universal feature of solid tumors: Acidity.
Funding snapshot
- Total raised
- $6.6MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $6.6M2023-06-12
Funding rounds
- Round, 2023
- $6.6M2023-06-12, SEC form D sold, 12 investors
Products
- Other
- Tumor Activated Permeability (TAP) Platform
Loading relationship preview